Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim
- Sudharsan Periyasamy-Thandavan†1,
- Suchreet Takhar†1,
- Adam Singer1,
- Michael Robert Dohn2,
- William Hutch Jackson1,
- April Eve Welborn1,
- Derek LeRoith3,
- Mario Marrero4,
- Muthusamy Thangaraju5, 6,
- Shuang Huang5, 6 and
- Patricia Veronica Schoenlein1, 6Email author
© Schoenlein et al.; licensee BioMed Central Ltd. 2012
Received: 5 May 2011
Accepted: 19 March 2012
Published: 19 March 2012
In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1.
IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors.
IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells.
his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effective treatment for women with high circulating levels of IGF-1, which have been correlated to a poor prognosis.
Breast cancer is a leading cause of cancer among women in the United States and approximately 60% to 70% of these breast cancers express estrogen receptor alpha (ERα) [1–3]. Estrogen binding to ERα induces both genomic and nongenomic actions of the ER, which ultimately lead to increased breast cancer cell growth. Over the past three decades, the selective estrogen-receptor modifier tamoxifen (TAM) has been used as an effective agent in adjuvant therapy and for the preoperative treatment for ER+ breast cancer. TAM acts as a competitive inhibitor and prevents estrogen binding to the ER, blocking the proliferative and prosurvival effects of estrogen. However, only about two thirds of all ER+ breast tumors are initially responsive to TAM therapy . Moreover, the development of resistance to TAM and other antiestrogens occurs often in breast cancer patients and is a major clinical concern [3, 5]. To understand the mechanisms of intrinsic and acquired resistance to antiestrogens, numerous in vitro studies have been conducted, and the multiple mechanisms described by these studies have been reviewed [5, 6]. However, it is still not clear which mechanisms commonly contribute to antiestrogen resistance in patients. Even with antihormonal therapies that severely deplete the estrogenic environment of the breast cancer cells, such as aromatase inhibitors, both inherent and acquired resistance occurs . The fact that antiestrogen resistance is still a major obstacle to successful antiestrogen therapy underscores the importance of investigating new therapies or identifying effective combination therapies for the treatment of ER+ breast cancer.
Because progesterone binding to the progesterone receptors (PRs), like estrogen binding to ERs, is growth stimulatory for breast cancer cells, using antagonists to both receptors to block tumor growth may be an attractive treatment option for ER+ and PR+ breast cancers. Such a combination therapy may be particularly applicable for breast cancer patients with PR A-rich tumors that typically show a poor disease-free survival rate . MIF, also referred to as RU486, is the most commonly used antiprogestin. MIF effectively antagonizes the activities of the PR and has served as a prototype antiprogestin to block PR function in various breast cancer cell models used in preclinical in vitro studies [reviewed in ]. Recent studies using in vivo models have further established a growth-stimulatory role for progestins and an important antitumor role for MIF and other antiprogestins [10, 11]. Further, a recent study on breast cell proliferation in premenopausal women provided evidence for a protective effect of MIF monotherapy on the breast epithelium through its ability to block breast epithelial cell proliferation .
In vitro studies conducted in ER+ breast cancer cell models by our laboratory [11, 13, 14] and others [15, 16] showed that the combination of an antiestrogen plus an antiprogestin induced significantly higher levels of cytostasis and cytotoxicity (cell death) than did treatment with the antiestrogen or antiprogestin used as a single agent. Our previous studies also showed superior efficacy of this combined treatment against antiestrogen-resistant, ER+ PR+ breast cancer cells in comparison to antiestrogen treatment . Further, our studies provided strong evidence that the antiproliferative effects of MIF are mediated primarily via its binding to the PR and not via binding to the glucocorticoid and mineralocorticoid receptors .
In preclinical studies, MCF-7 cells, which express both ER and PR, have often served as the prototype ER+ breast cancer model system. MCF-7 cells show E2-dependent growth and are growth stimulated by progestin binding to the PR [11, 14, 17]. In addition, IGF-1 stimulates the proliferation of MCF-7 cells, and cross-talk between ER and IGF-1R is required to stimulate maximal growth of MCF-7 cells . IGF-1 binding to IGF-1R activates its tyrosine kinase activity and downstream signaling cascades , which include the phosphorylation and activation of MEK1/MAPK1/2 and PI3K/AKT signaling . Activation of MAPK1/2, also referred to as extracellular signal-regulated-kinases ERK1 (p44) and ERK2 (p42), and AKT can ultimately increase breast cancer cell proliferation  and survival [22, 23]. AKT-mediated signaling is viewed as a determinant in a breast cancer response to antiestrogen treatment . A key role for AKT signaling in endocrine response is supported by the recent clinical study in which the targeting of mTOR, a downstream effector of AKT, sensitized ER+ breast cancers to aromatase inhibitors . MEK1/MAPK signaling also regulates cell growth and/or differentiation, but is not typically thought of as a key antiestrogen resistance mechanism or as a key effector of cell survival in breast cancer cells undergoing hormonal therapy . However, MEK1 activation and subsequent phosphorylation of the MAPKs is associated with a poor response to antihormonal therapy and decreased patient survival in clinical breast cancer [27, 28], and a recent study determined that blockade of MAPK affects co-repressor recruitment and potentiates 4-OHT action .
In this study, we demonstrate a critical prosurvival role for the IGF-1/MEK1signaling axis in breast cancer cells undergoing antiestrogen and antiprogestin treatment and uniquely demonstrate that the underlying mechanism of MEK1-mediated survival is via blockade of the proapoptotic action of the BH3-only protein BimEL.
Materials and methods
MCF-7 and T-47D ER+ breast adenocarcinoma cells (early passage) were procured from the American Type Culture Collection (Rockville, MD, USA) and cultured, as previously described [17, 30]. Before hormonal treatments, cells were placed in DMEM-F12 medium (Invitrogen, Carlsbad, CA, USA), supplemented with 5% dextran-coated charcoal stripped fetal bovine serum (DCC FBS; Hyclone, Logan UT, USA), 2% antibiotics-antimycotics (Invitrogen), 1% sodium pyruvate (Invitrogen) and 10 μg/ml insulin (Sigma-Aldrich, St Louis, MO, USA). For hormonal treatments, cells were seeded either in the absence or presence of insulin, allowed to adhere to the culture vessel for 16 to 24 hours, and then treated with one of the following: 10 nM estradiol (E2; Sigma), 10 nM E2 plus 1 μM 4-OHT in the presence or absence of 10 μM MIF (Sigma Aldrich). For experiments in which cells were seeded in medium containing insulin, cells were washed with HBSS to remove insulin, before administration of hormonal treatment. As indicated in the text and figure legends, hormonal treatments also were conducted in the presence of the following agents alone or in combination: 10 μ;g/ml Insulin (Sigma),1-20 ng/ml IGF-1 (Novozymes/Gropep, North Rocks, NSW, Australia), 5 μM U0126 (EMD Biosciences, Billerica, MA, USA), 25 or 50 μ;M PD 98059 (Calbiochem), and/or 500 μ;M vitamin E (Sigma Aldrich).
Cell counts and clonogenic assay
Cells were evenly seeded in triplicate at a density to attain 50% to 70% confluence within 24 hours and treated with drugs and/or hormones, as described in the figure legends. For cell counts of the detached cell population, detached cells were collected, concentrated by centrifugation, and counted by using a hemacytometer. Adherent cells were washed twice with cold 1× PBS, trypsinized, diluted in Isoton II, and counted by using a Coulter Counter. For total cell counts, the adherent, monolayer cells were released from the culture dish by trypsinization and pooled with the detached cells collected from the medium. Before all cell counts, the cells were syringed 3 times with a 25 7/8-gauge needle to obtain single-cell suspension. Where indicated in the figure legends, trypan blue (0.08%; Sigma Aldrich) was added to the cell suspension for the identification of dead cells; trypan blue-positive cells demonstrate compromised plasma membrane integrity in dying or dead cells. Cell counts are graphed as the mean ± SD values, and statistically significant differences between treatment groups are described in the figure legends.
Mitochondrial membrane depolarization assay
The mitochondrial depolarization assay was conducted by using the compound 5,5',6,6- tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine, also referred to as JC-1, according to the manufacturer's protocol (Biotium, Inc., Hayward, CA, USA) and as previously described by our laboratory . All experiments were performed in triplicate. The results are expressed as the mean ± SD values, and statistically significant differences between treatment groups are described in the figure legends.
Protein harvest, immunoblotting, and λ-phosphatase treatment
Cell lysates were harvested as described in our previous studies [13, 17, 30, 31]. Immunoblotting was conducted according to the manufacturer's protocol by using primary antibodies to: LC3 (ab48394), p62 (ab56416), cleaved lamin A (ab52300) [Abcam]; cleaved PARP (9541), phospho-p44/42 MAP kinase (Thr202/Tyr204, 9106), total MAPK (9102), Akt (9272), phospho-Akt (Ser473, 9271), MEK1 (9124), pBim (4581), and Bim (2819) [Cell Signaling]; pERK1/2 (SC-7383), ERα (SC-8002), and IGF-1Rβ (SC-713) [Santa Cruz Biotechnology]; and β-actin (A5441) [Sigma]. Secondary antibodies included antimouse IgG (715-035-150) and anti-rabbit IgG (711-035-152) [Jackson ImmunoResearch]. Immunodetection was performed by using the ECL detection system (34080; Thermo Scientific Pierce) and HyBlot CL autoradiography film (E3012, Denville Scientific Inc., Parsippany, NJ, USA). Densitometry was used to compare signal intensity among samples by using β-actin as the loading control.
For phosphatase experiments, cell lysates were prepared and analyzed as recently described  in a triton-based lysis buffer with protease inhibitors, but not NaF or Na3VO4. The lysates (50 μ;g protein) were incubated for 20 minutes or 1 hour with lambda phosphatase (λ-PPase (15 μ;g/200 U) (NEB; PO753S) or calf alkaline phosphatase (CIP, 50 U) (NEB, M02909), according to the manufacturer's recommendations.
Detection of cleaved cytokeratin 18
Evenly seeded adherent cells were treated with the drugs and/or hormones for 48, 72, and 96 hours. Detached and adherent cells were collected and lysed in ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4/10 mM MgCl2/150 mM NaCl/0.5% NP-40), and the cleavage of cytokeratin 18 was measured in the cell extracts by using Peviva M30-Apoptosense ELISA, according to the manufacturer's protocol (DiaPharma, West Chester, OH, USA). Three independent experiments were performed for each treatment group. Values expressed as the mean ± SD and statistically significant differences between treatment groups are described in the figure legends.
Reactive oxygen species (ROS) determination
MCF-7 cells (5 × 104 cells in 200 μl per well of a 96-well dish) were seeded. After 24 hours to allow cell attachment, cells were treated with the drugs and/or hormones for various times. At the end of the experimental period, the cells were washed with HBSS and loaded with 25 μM 5(6)-carboxy-2',7'-dichlorofluorescein diacetate (CM-H2DCFDA, C6827; Invitrogen) for 30 minutes. This nonfluorescent ester CM-H2DCFDA enters cells and is deacetylated to nonfluorescent 5-(and -6)-chloromethyl- 2',7'-dichlorodihydrofluorescein (CM-H2DCF) by cellular esterases. ROS rapidly oxidizes CM-H2DCF to the highly fluorescent 5- (and 6-) chloromethyl-2',7'-DCF (CM-DCF). After 30 minutes of incubation, intracellular ROS levels are directly proportional to CM-DCF generation. To quantify the level of intracellular CM-DCF, the cells were washed with HBSS to remove extracellular CM-DCF, treatment medium was replaced, and cells were incubated at 37°C for a short recovery period (0 to 5 minutes). CM-DCF fluorescence was measured at an excitation wavelength of 485 nm and emission at 520 nm on a fluorescent plate reader (Tecan Spectraflour Plus). Values are expressed as mean ± SD of three independent experiments, and statistically significant differences between treatment groups are described in the figure legends.
Downregulation of MEK1 or Bim with RNA interference
RNA interference (RNAi) targeted to MEK1 or Bim (M-003571-00 and M004383-02-0020, respectively, Dharmacon) was carried out according to the manufacturer's protocol. Cells were seeded in DMEM-F12 medium containing 5% DCC FBS (antibiotic free). Twenty-four hours after seeding, cells were washed and treated with either MEK- or Bim-targeting RNAi by using Oligofectamine (Invitrogen; 12252-011). For controls, cells were treated with scrambled RNAi. Twenty-four or forty-eight hours after RNAi treatment, the cells were treated with drugs and/or hormones for various times, and harvested for either protein analysis or cell counts.
Overexpression of MEK1 cDNAs
A MEK1-GFP plasmid expression vector  was purchased from Addgene (Plasmid 147461; Billerica, MA, USA), and the pEGFP-N1 parent vector, from Clonetech, 6085-1. Twenty-four hours before transfection, MCF-7 cells were seeded in DMEM-F12 medium containing 5% DCC FBS (antibiotic free) to yield approximately 50% confluence. Cells were then transfected with plasmids (4.0 μg) by using lipofectamine LTX (Invitrogen) according to the manufacturer's protocol. The transfected cell population was maintained in culture medium for 24 hours, treated with drugs for various times, and harvested for either ROS determinations, mitochondrial membrane permeabilization, or protein analysis.
Infections with recombinant adenovirus expressing MEK1
Recombinant adenovirus  expressing dominant-negative MEK1 (Ad-CMV-MEK1DN, Cat 1165; Vector Biolabs) or the Ad-CMV-Null control vector (Ad-CMV, Cat 1300; Vector Biolabs)  was used to infect cells at an estimated multiplicity of infection of 100, which results in > 80% infection of ER+ breast cancer cells. Twenty-four hours after infection, cells were treated with hormones and/or drugs for various times, and harvested for either ROS determinations, mitochondrial membrane permeabilization, or protein analysis.
For all experiments in which data are graphed as the mean ± SD values, a minimum of three independent experiments was performed. Comparisons were made between treatment groups, and statistically significant differences were determined by one-way ANOVA by using Sigma Plot 11 for Windows, as identified in the figure legends.
Physiologic levels of IGF-1 inhibit 4-OHT- and MIF-induced cell death by reducing the levels of oxidative stress in MCF-7 breast cancer cells
Once we established that 20 ng/ml IGF-1 maximally induced cell proliferation, while blocking cell detachment (Figure 1 and data not shown), this concentration was used in all subsequent experiments, including the experiments shown in Figure 1 (b through d), in which we further characterized the IGF-1 prosurvival action. Specifically, IGF-1-treated cells showed very low levels of cleaved PARP and lamin A (Figure 1b). Further IGF-1 blocked the ability of 4-OHT and/or MIF treatment to affect the cleavage of cytokeratin 18 (Figure 1c) and depolarize the mitochondrial membrane (Figure 1d). Cytokeratin 18 cleavage, in particular, occurs during caspase-dependent apoptosis in epithelial cells and tumors derived from epithelial cells . Thus, IGF-1, at physiologically relevant concentrations, blocks 4-OHT-induced and/or MIF- induced apoptotic cell death, which has been partially characterized in our previous studies and involves the activation of caspase-9, -8, and -6 [17, 30].
Blockade of MEK1 activity with small-molecule inhibitors abrogates the antiapoptotic effects of IGF-1 in hormonally treated ER+ MCF-7 breast cancer cells
To determine whether the apparent MEK1 activity imparted a growth or survival advantage to 4-OHT- and/or MIF- treated cells, we combined the small-molecule MEK1 inhibitors PD 98059  or U0126  with the hormonal treatments. In initial experiments, we determined that PD 98059 and U0126 effectively blocked IGF-1-and E2-induced MEK1 activity, as evidenced by the lack of detectable MAPK1/2 phosphorylation, with minimal affect on Akt phosphorylation (Figure 3b; compare lanes 9 to 12 with lanes 5 to 9 and data not shown). Importantly, PD 98059 treatment restored the basal and induced level of cell detachment (Figure 3c) and cleavage of PARP in the (Figure 3d) cell populations undergoing 4-OHT and/or MIF treatment, in addition to reducing cell proliferation in all treatment groups (Figure 3c). In a similar fashion, treatment with U0126 also blocked the proliferative (data not shown) and prosurvival effects of IGF-1 and restored the cytotoxic action of 4-OHT and MIF, which included enhancing ROS levels and increasing the percentage of mitochondrial membrane depolarization (see Additional files 2a and 2b). Treatment with vitamin E again reduced the levels of ROS, mitochondrial membrane depolarization, and cleavage of PARP and lamin A resulting from MEK1 blockade (see Additional files 2c through 2e). Considered together, these data show that small-molecule inhibitors of MEK1 effectively block the proliferative and antiapoptotic action of IGF-1 and enhance the ability of 4-OHT and MIF to induce an ROS-dependent apoptosis in ER+ MCF-7 breast cancer cells.
Blockade of MEK1 effectively induces death of MCF-7 cells with reduced IGF-1R levels
MEK1 function is required to reduce ROS, which is a prerequisite of antiestrogen- and/or antiprogestin-induced cell death
MEK1 blockade in antiestrogen and antiprogestin breast cancer cells induces ROS and cell death via a Bim-dependent mechanism
Close inspection of a lighter exposure of the BimEL signal (Figure 6a, middle panel) identified a doublet band, with the upper band being the predominant form in cells treated with E2 plus IGF-1 (Figure 6a, lane 5). The lower BimEL band, which is a faster-migrating BimEL protein, was consistently detected at higher levels in cells treated with U0126 as a single agent or in combination with 4-OHT (Figure 6b; compare lanes 3 and 4 with lanes 1 and 2 and lanes 7 and 8 with lanes 5 and6), and/or MIF treatment (Figure 6c and data not shown). In addition, this lower band was often detected at higher levels than the upper BimEL band in cells treated with 4-OHT and/or MIF for 60 hours or longer in medium devoid of IGF-1 (data not shown). Overall, the relative increase in the levels of the lower BimEL band correlated to the timing of 4-OHT- and/or MIF-induced cytotoxicity in MCF-7 populations. We predicted that the lower BimEL band was the dephosphorylated form of BimEL known to be more stably maintained in cells. To determine whether phosphorylation was regulating the levels of either BimEL form, we treated cells with MG132, a commonly used proteasome inhibitor, which blocks the degradation of ubiquitinated proteins by the proteasome . In these experiments, the upper BimEL protein accumulated in cells treated with MG132 plus E2, 4-OHT, and/or MIF (Figure 6i; compare lanes 5 and 6 with lanes 1 and 2 and data not shown). In contrast, in the cell populations treated with PD 98059 or U0126, the phosphorylation of BimEL was impaired and did not significantly increase after MG132 treatment (Figure 6i, compare lanes 7 and 8 with lanes 5 and 6). Further, the dephosphorylated status of the lower Bim EL band was established when protein lysates isolated from cells exposed to the different hormones were subjected to calf-intestinal-phosphatase (data not shown) or λ-phosphatase. Figure 6d shows representative results of λ-phosphatase treatments conducted for 20 minutes and 1 hour that resulted in increased levels of the lower BimEL band (Figure 6d; compare lane 1 with lanes 2 and 3, respectively). The increase in the lower BimEL band occurred with a concomitant loss of the upper BimEL band (Figure 6e; compare lane 1 with lanes 2 and 3, respectively) and was similar in size to the BimEL form generated by treatment of cells with U0126 (Figure 6e; compare lanes 2 through 4). In comparison, the λ-phosphatase treatment of protein isolated from cells treated with U0126 only modestly increased the levels of the lower BimEL band (Figure 6e; compare lane 5 with lane 4). As an internal control, the loss of pMAPK signal as a result of CIP (data not shown) and λ-phosphatase treatment was apparent in all experiments (Figure 6e; lanes 2 and 3 compared with lane 1, and lane 5 compared with lane 4). Thus, these experiments identify the lower BimEL band as the dephosphorylated from of BimEL.
Because studies of CYP2D6 polymorphisms do not clearly show that 4-OHT is a key metabolite involved in the antitumor effects of TAM treatment in patients , we also performed similar experiments with TAM at a dose of 5.0 μ;m, commonly used for preclinical in vitro studies . The results of these experiments showed that IGF-1 also reduced the ability of TAM, used as a single agent or in combination with MIF, to induce cell death (Figure 6f, lane 3 compared with lane 7, and data not shown); targeting MEK1 with inhibitors led to a robust increase in the levels of dephosphorylated BimEL, with a concomitant decrease in the levels of phosphorylated BimEL; and the levels of dephosphorylated Bim EL correlated directly to the cytotoxicity of MEK1 blockade, as evidenced by increased PARP cleavage in cells by 72 hours of treatment (Figure 6f; lanes 8 and 9 compared with lanes 6 and 7).
The inherent expression level of BimEL in ER+ breast cancer cells correlates with the magnitude of apoptosis induced by 4-OHT and/or MIF treatments conducted in the presence or absence of MEK1 blockade
In this study, we provide evidence that an improved treatment approach for ER+ breast cancer could be the use of antiestrogen and/or antiprogestin therapy in combination with the targeted blockade of the dual-specificity MEK1 kinase. Specifically, this study used a variety of expression vectors, siRNA targeting, and small-molecule inhibitors of MEK kinase to demonstrate the following key data: (a) physiologic levels of IGF-1 protect ER+ breast cancer cells from antiestrogen- and antiprogestin-induced cell death through an MEK1-dependent mechanism; (b) MEK1 activation blocks ROS induction and/or accumulation that is required for antiestrogen- and antiprogestin-induced apoptotic cell death; and (c) MEK1 blockade circumvents IGF-1-mediated protection and induces a Bim-dependent, ROS-mediated apoptotic cell death in antiestrogen- and/or antiprogestin-treated breast cancer cells.
Our studies are based on the hypothesis that targeting PR along with ER should more effectively reduce breast cancer cell growth than does treatment with an antiestrogen, because progesterone, like estrogen, is mitogenic in the breast  and drives mammary tumor proliferation in multiple model systems. Consistent with a mitogenic role for PR in breast cancer, an in vivo preclinical study [54, 55] recently showed that MIF treatment actually prevented the development of mammary carcinogenesis in mice carrying a mutated BRCA1 gene . Thus, targeting the PR with an antiprogestin like MIF along with antiestrogen therapy should have added benefit for all ER+ breast cancer patients, and particular benefit for patients with ER+, antiestrogen-unresponsive tumors. For example, blockade of the PR may be quite effective for the subpopulation of ER+ breast cancers identified by Fuqua and colleagues  that are PR-A-rich and show a very poor disease-free survival rate after antiestrogen therapy. The fact that MIF treatment is well tolerated and can block breast epithelial cell proliferation in premenopausal women  lends further support for MIF or other antiprogestins currently being developed [11, 54] to be used in combination with antiestrogen therapy. To date, only three clinical trials have been conducted with MIF. In these trials, MIF was used as a monotherapy [reviewed in ], and two of the trials showed efficacy of MIF monotherapy similar to that of TAM therapy against metastatic breast cancer.
In support of targeting both ER and PR as a treatment approach to breast cancer, our past studies demonstrated that 4-OHT and MIF more effectively induce growth arrest and cell death than do either 4-OHT or MIF treatment of ER+PR+, antiestrogen-sensitive [13, 14], and ER+PR+, antiestrogen-resistant breast cancer cells . Improved efficacy was also seen when the antiestrogen ICI 182, 780 (faslodex) was combined with MIF . Previous in vivo studies with human breast cancer xenografts in nude mice determined that TAM-plus-MIF combined treatment effected a more-robust antitumor response than did TAM or MIF . This study still continues to support the concept of using TAM-plus-MIF combination therapy because this combined treatment induced a robust cytostatic response in ER+ breast cancer cells treated in medium supplemented with IGF-1, even though the cytotoxic effects of the combined treatment were markedly attenuated by IGF-1. Overall, IGF-1 appears to convert hormonally induced cytotoxicity to a cytostatic outcome. Because cytostasis is not a terminal state, breast cancer cells treated in the presence of IGF-1 could potentially escape antiestrogen- and/or antiprogestin-induced cytostasis via genetic or epigenetic changes that lead to the development of resistance. Thus, the use of an antiestrogen with an antiprogestin may not completely alleviate problems of resistance, particularly in patients with high circulating levels of IGF-1 .
Combining a MEK1 inhibitor with antiestrogen and/or antiprogestin treatment very effectively blocked the proliferative and antiapoptotic effects of IGF-1 in MCF-7 cells. Thus, MEK1 appears to be a key to breast cancer cell survival and proliferation. A critical prosurvival role of MEK1 in breast cancer cells is supported by elegant studies from the Eastman laboratory, which demonstrated a more critical role of MEK1/MAPK signaling in breast cancer cell survival than that of Akt signaling . Our study, however, is quite distinct from the study by the Eastman laboratory, which did not use hormonal therapy, or identify the key role of the proapoptotic BimEL protein in mediating death in response to MEK1 blockade in hormonally treated breast cancer cells. In more recent studies, a prosurvival role for MEK1 in blocking the cytotoxicity of TNF-α against MCF-7 cells has also been demonstrated . Thus, recognition of an important role is growing for MEK1-mediated signaling in breast cancer cell survival.
Not all published studies concur with a key prosurvival role for MEK1 in hormonally treated breast cancer cells. For example, Dufourny et al.  reported that mitogenic signaling induced by IGF-1 in MCF-7 human breast cancer cells was independent of the mitogen-activated protein kinases (MAPK1/2) and that PD 98059 was unable to restore antiestrogen efficacy. In their study, PI3-K-induced signaling mediated survival. We believe that one explanation for inconsistencies in the reported role(s) of MEK1 versus that of AKT is the potential variation in MCF-7 cell lines between laboratories. This variation can result for a number of reasons, including the length of passage of the MCF-7 cells; (that is, early versus late passage ) and the fact that an inherent clonal heterogeneity within the MCF-7 cell line itself  can easily result in the selection of cells with the fastest proliferation rates. The MCF-7 cells used in this study were cultured from early-passage MCF-7 cells (ATCC), still maintain inducible MEK/MAPK signaling, and do not show constitutive PI3K/Akt signaling. However, a recent study in lung cancer cells demonstrated that constitutive AKT expression reduced the level of BimEL expression to such an extent that, even with MEK1 blockade, apoptosis was not induced . So it will be important to investigate how constitutive Akt activation affects the IGF-1/MEK1 prosurvival axis described in this study.
Of particular importance, this study provides strong evidence that not merely the levels of BimEL in cells determine a cytotoxic outcome. More important, it appears that the conversion of phosphorylated BimEL to the dephosphorylated form is a key to the BimEL proapoptotic action. Nonetheless, the intrinsic level of BimEL expression is important, as seen by the studies using the T-47D breast cancer cells. We show that T-47D cells express lower levels of basal BimEL protein and do not readily undergo hormonally induced apoptotic cell death, even when cells are treated with an MEK1 inhibitor. So, targeting MEK1 may not yield optimal BimEL-induced apoptosis in all breast cancer patients undergoing endocrine therapy for ER+, luminal-type breast cancers. To identify the breast cancer patients that will benefit from MEK1 targeting, it will be important to determine the various mechanisms regulating BimEL expression and function in T-47D cells and in other breast cancer cell models that express low levels of Bim. To this end, our current studies are aimed at understanding the multiple pathways that modulate BimEL expression and function in different ER+ breast cancer cell models. With the knowledge that BimEL can affect death in ER+ breast cancer cells treated with antiestrogens, it is interesting to speculate that the overexpression of Bcl2 that has been identified in antiestrogen-resistant sublines and breast cancers  may be selected, in part, by the cancer cell survival being dependent on blocking the cytotoxic action of BimEL, as Bcl2 binding to BimEL can abrogate the BimEL ability to induce apoptosis .
Although not a main focus of this article, the prosurvival effects of vitamin E (α-tocopherol) described in this study should be noted. Vitamin E effectively blocked apoptosis induced by 4-OHT and MIF, in the absence and presence of MEK1 blockade. Vitamin E treatment specifically reduced ROS in cells undergoing these treatments. A recent study from the Poirot laboratory  similarly showed that vitamin E blocked TAM induced breast cancer cell death by inhibiting the production of oxysterols and ROS. It does appear that at least part of the cytotoxic action of TAM, 4-OHT, and other SERMs results from their binding to high-affinity microsomal antiestrogen binding sites (AEBS), which alters cholesterol metabolism in such a manner that oxysterols and ROS accumulate in breast cancer cells [63–65]. Whether the increased ROS generated due to MEK1 blockade somehow results from a similar impairment of cholesterol metabolism remains to be determined. However, it is clear that vitamin E blocks the ROS induction/accumulation that results from MEK1 blockade during antiestrogen and/or antiprogestin treatments and that the abrogation of ROS blocks breast cancer cell death. From these data, it is tempting to speculate that breast cancer patients undergoing antiestrogen therapy may benefit from a diet low in vitamin E. Minimally, further studies are needed the better to define the mechanism of action of vitamin E, its effect on the MEK1/MAPK prosurvival axis that contributes to the regulation of the Bim proapototic action, and its effect on the efficacy of endocrine therapy for breast cancer.
In breast cancer tissue from patients, the downregulation of Bim expression has been associated with breast cancer progression, in conjunction with downregulation of SIAH1 expression . However, we are unaware of any studies analyzing Bim expression levels relative to endocrine efficacy in patients. Interestingly, Butt and colleagues  recently reported that PUMA levels in a small cohort of breast cancer patients predict patient outcome and tamoxifen responsiveness. PUMA, like Bim, is a BH3-only protein of the Bcl2 family of proteins and an apoptotic regulator. PUMA downregulation was shown to mediate an apoptotic response to TAM in human breast cancer cells, but manipulation of PUMA levels alone was unable to ameliorate completely TAM-induced apoptosis . Butt and colleagues proposed that there is a "complex interplay between numerous apoptotic regulators in coordinating the cytotoxic, endocrine response." Our data are in full agreement with this prediction and support the conclusion that dephosphorylated Bim EL will be one of the apoptotic regulators important in predicting endocrine response. An already-known interplay exists between Bim and Puma proteins in regulating taxane-induced cell death in breast cancer cells. In this response, PUMA displaces Bim from binding Bcl2, so Bim is free to affect negatively the mitochondrial integrity and execute its proapoptotic function . Our study, combined with these recent studies, allow us to predict that the regulation of Bim, along with PUMA in breast cancer cells, will be pivotal to their response to hormonal therapy and some chemotherapies.
This study has identified the IGF-1/IGF-IR/MEK prosurvival axis that exists in ER+ breast cancer cells to attenuate significantly the cytotoxic action of antiestrogen and antiprogestin treatment, with little effect on the antiproliferative action of these hormones. We further identified BimEL as the death effector being regulated by the IGF-1/IGF-IR/MEK prosurvival axis. Targeting MEK1 in conjunction with hormonal therapy as an initial treatment option would be a new approach and should be considered, because the recurrence of breast cancer in women receiving SERMs is still a major clinical challenge, and a large number of ER+ breast cancers are initially resistant to antiestrogen therapy, possibly due to IGF-1-mediated survival effects .
insulin-like growth factor-1
insulin-like growth factor receptor
mitogen-activated protein kinase
MEK1-dominant negative kinase
- cl PARP:
cleaved poly-ADP ribose polymerase
reactive oxygen species
We thank Dr. Vadivel Ganapathy for critical reading of this manuscript. This work was supported by NIH grants CA70897 and CA121438 to P.V.S.
- Cutler W, Burki R, Genovesse E, Zacher M: Breast cancer in postmenopausal women: what is the real risk?. Fertil Steril. 2009, 92: S16.View ArticleGoogle Scholar
- SEER Cancer Statistics Review, 1975-2007. Edited by: Altekruse SFKC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK. 2009, Bethesda, MD: National Cancer Institute
- Jordan VC, O'Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007, 25: 5815-5824. 10.1200/JCO.2007.11.3886.View ArticlePubMedGoogle Scholar
- Herynk MH, Fuqua SA: Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol. 2007, 608: 130-143. 10.1007/978-0-387-74039-3_10.View ArticlePubMedGoogle Scholar
- Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9: 631-643. 10.1038/nrc2713.View ArticlePubMedGoogle Scholar
- Schoenlein PV, Periyasamy-Thandavan S, Samaddar JS, Jackson WH, Barrett JT: Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance. Autophagy. 2009, 5: 400-403. 10.4161/auto.5.3.7784.View ArticlePubMedGoogle Scholar
- Chumsri S, Howes T, Bao T, Sabnis G, Brodie A: Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol. 2011, 125: 13-22. 10.1016/j.jsbmb.2011.02.001.View ArticlePubMedPubMed CentralGoogle Scholar
- Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA: Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004, 10: 2751-2760. 10.1158/1078-0432.CCR-03-0141.View ArticlePubMedGoogle Scholar
- Klijn JG, Setyono-Han B, Foekens JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000, 65: 825-830. 10.1016/S0039-128X(00)00195-1.View ArticlePubMedGoogle Scholar
- Liang Y, Besch-Williford C, Brekken RA, Hyder SM: Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res. 2007, 67: 9929-9936. 10.1158/0008-5472.CAN-07-1103.View ArticlePubMedGoogle Scholar
- El Etreby MF, Liang Y: Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat. 1998, 49: 109-117. 10.1023/A:1006098910000.View ArticlePubMedGoogle Scholar
- Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K: The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod. 2008, 23: 2072-2079. 10.1093/humrep/den228.View ArticlePubMedGoogle Scholar
- Schoenlein PV, Hou M, Samaddar JS, Gaddy VT, Thangaraju M, Lewis J, Johnson M, Ganapathy V, Kallab A, Barrett JT: Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol. 2007, 31: 643-655.PubMedGoogle Scholar
- El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV: Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1998, 51: 149-168. 10.1023/A:1006078032287.View ArticlePubMedGoogle Scholar
- Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res. 1987, 47: 1441-1448.PubMedGoogle Scholar
- Thomas M, Monet JD: Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab. 1992, 75: 865-870. 10.1210/jc.75.3.865.PubMedGoogle Scholar
- Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV: Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res. 2004, 10: 5215-5225. 10.1158/1078-0432.CCR-03-0637.View ArticlePubMedGoogle Scholar
- Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W: Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids. 2009, 74: 586-594. 10.1016/j.steroids.2008.11.020.View ArticlePubMedGoogle Scholar
- Neuenschwander S, Roberts CT, LeRoith D: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology. 1995, 136: 4298-4303. 10.1210/en.136.10.4298.PubMedGoogle Scholar
- Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X: The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci. 2008, 13: 3273-3287.View ArticlePubMedGoogle Scholar
- Lobenhofer EK, Huper G, Iglehart JD, Marks JR: Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 2000, 11: 99-110.PubMedGoogle Scholar
- Yan Y, Haas JP, Kim M, Sgagias MK, Cowan KH: BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. J Biol Chem. 2002, 277: 33422-33430. 10.1074/jbc.M201147200.View ArticlePubMedGoogle Scholar
- Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev. 1999, 13: 2905-2927. 10.1101/gad.13.22.2905.View ArticlePubMedGoogle Scholar
- Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010, 120: 2406-2413. 10.1172/JCI41680.View ArticlePubMedPubMed CentralGoogle Scholar
- Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012, 366: 520-529. 10.1056/NEJMoa1109653.View ArticlePubMedGoogle Scholar
- Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB: MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene. 2002, 21: 4000-4008. 10.1038/sj.onc.1205506.View ArticlePubMedGoogle Scholar
- Gee JM, Robertson JF, Ellis IO, Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer. 2001, 95: 247-254. 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- Donovan JC, Milic A, Slingerland JM: Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem. 2001, 276: 40888-40895. 10.1074/jbc.M106448200.View ArticlePubMedGoogle Scholar
- Hong W, Chen L, Li J, Yao Z: Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells. Biochem Biophys Res Commun. 2010, 396: 299-303. 10.1016/j.bbrc.2010.04.085.View ArticlePubMedGoogle Scholar
- Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, Browning D, Rawson J, Smith SB, Barrett JT, Schoenlein PV: A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther. 2008, 7: 2977-2987. 10.1158/1535-7163.MCT-08-0447.View ArticlePubMedGoogle Scholar
- Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV: Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy. 2010, 6: 19-35. 10.4161/auto.6.1.10323.View ArticlePubMedGoogle Scholar
- O'Reilly LA, Kruse EA, Puthalakath H, Kelly PN, Kaufmann T, Huang DC, Strasser A: MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation. J Immunol. 2009, 183: 261-269. 10.4049/jimmunol.0803853.View ArticlePubMedPubMed CentralGoogle Scholar
- Yao Z, Flash I, Raviv Z, Yung Y, Asscher Y, Pleban S, Seger R: Non-regulated and stimulated mechanisms cooperate in the nuclear accumulation of MEK1. Oncogene. 2001, 20: 7588-7596. 10.1038/sj.onc.1204963.View ArticlePubMedGoogle Scholar
- Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Haussinger D, Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P: 17-Allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol Cancer Ther. 2010, 9: 1378-1395. 10.1158/1535-7163.MCT-09-1131.View ArticlePubMedPubMed CentralGoogle Scholar
- Tian N, Arany I, Waxman DJ, Baliga R: Cytochrome-P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity in glomerular epithelial cells. Kidney Int. 2010, 78: 182-190. 10.1038/ki.2010.100.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother. 1995, 49: 415-421. 10.1016/0753-3322(96)82678-3.View ArticlePubMedGoogle Scholar
- Hagg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman KG, Shoshan M, Linder S: A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs. 2002, 20: 253-259. 10.1023/A:1016249728664.View ArticlePubMedGoogle Scholar
- Prasad V, Chandele A, Jagtap JC, Sudheer Kumar P, Shastry P: ROS-triggered caspase 2 activation and feedback amplification loop in beta-carotene-induced apoptosis. Free Radic Biol Med. 2006, 41: 431-442. 10.1016/j.freeradbiomed.2006.03.009.View ArticlePubMedGoogle Scholar
- Oh YI, Kim JH, Kang CW: Oxidative stress in MCF-7 cells is involved in the effects of retinoic acid-induced activation of protein kinase C-delta on insulin-like growth factor-I secretion and synthesis. Growth Horm IGF Res. 2010, 20: 101-109. 10.1016/j.ghir.2009.10.003.View ArticlePubMedGoogle Scholar
- Ripple MO, Kalmadi S, Eastman A: Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Breast Cancer Res Treat. 2005, 93: 177-188. 10.1007/s10549-005-4794-6.View ArticlePubMedGoogle Scholar
- Whyte J, Bergin O, Bianchi A, McNally S, Martin F: Key signalling nodes in mammary gland development and cancer: mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 2009, 11: 209-10.1186/bcr2361.View ArticlePubMedPubMed CentralGoogle Scholar
- Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ: Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell. 1997, 90: 859-869. 10.1016/S0092-8674(00)80351-7.View ArticlePubMedGoogle Scholar
- Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000, 351: 95-105. 10.1042/0264-6021:3510095.View ArticlePubMedPubMed CentralGoogle Scholar
- Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993, 53: 3736-3740.PubMedGoogle Scholar
- Balmanno K, Cook SJ: Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009, 16: 368-377. 10.1038/cdd.2008.148.View ArticlePubMedGoogle Scholar
- Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ: Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem. 2004, 279: 8837-8847. 10.1074/jbc.M311578200.View ArticlePubMedGoogle Scholar
- O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, Huang DC: Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 1998, 17: 384-395. 10.1093/emboj/17.2.384.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamaguchi T, Okada T, Takeuchi K, Tonda T, Ohtaki M, Shinoda S, Masuzawa T, Ozawa K, Inaba T: Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator. Gene Ther. 2003, 10: 375-385. 10.1038/sj.gt.3301897.View ArticlePubMedGoogle Scholar
- Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998, 8: 397-403. 10.1016/S0962-8924(98)01346-4.View ArticlePubMedGoogle Scholar
- Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM: Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer. 2011, doi: 10.1002/cncr.26407Google Scholar
- Roberts CG, Millar EK, O'Toole SA, McNeil CM, Lehrbach GM, Pinese M, Tobelmann P, McCloy RA, Musgrove EA, Sutherland RL, Butt AJ: Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene. 2011, 30: 3186-3197. 10.1038/onc.2011.36.View ArticlePubMedGoogle Scholar
- Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC, Lam EW: FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 2003, 278: 49795-49805. 10.1074/jbc.M309523200.View ArticlePubMedGoogle Scholar
- Clarke CL, Sutherland RL: Progestin regulation of cellular proliferation. Endocr Rev. 1990, 11: 266-301. 10.1210/edrv-11-2-266.View ArticlePubMedGoogle Scholar
- Wiehle RD, Christov K, Mehta R: Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol Rep. 2007, 18: 167-174.PubMedGoogle Scholar
- Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY: Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006, 314: 1467-1470. 10.1126/science.1130471.View ArticlePubMedGoogle Scholar
- Tworoger SS, Rosner BA, Willett WC, Hankinson SE: The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2011, 13: R99-10.1186/bcr3040.View ArticlePubMedPubMed CentralGoogle Scholar
- Sivaprasad U, Basu A: Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-alpha-induced cell death in MCF-7 cells. J Cell Mol Med. 2008, 12: 1265-1271. 10.1111/j.1582-4934.2008.00282.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH, Sussenbach JS: Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 1997, 272: 31163-31171. 10.1074/jbc.272.49.31163.View ArticlePubMedGoogle Scholar
- Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, Pauley RJ, Willson JK, Zborowska E, Brattain MG: Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells. J Cell Physiol. 1998, 176: 424-434. 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.0.CO;2-1.View ArticlePubMedGoogle Scholar
- Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA: Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One. 2010, 5: e13026-10.1371/journal.pone.0013026.View ArticlePubMedPubMed CentralGoogle Scholar
- Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, Wang Y, Zwart A, Nehra R, Liu MC: Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol. 2009, 114: 8-20. 10.1016/j.jsbmb.2008.12.023.View ArticlePubMedPubMed CentralGoogle Scholar
- Hubner A, Barrett T, Flavell RA, Davis RJ: Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell. 2008, 30: 415-425. 10.1016/j.molcel.2008.03.025.View ArticlePubMedPubMed CentralGoogle Scholar
- Payre B, de Medina P, Boubekeur N, Mhamdi L, Bertrand-Michel J, Terce F, Fourquaux I, Goudouneche D, Record M, Poirot M, Silvente-Poirot S: Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther. 2008, 7: 3707-3718. 10.1158/1535-7163.MCT-08-0507.View ArticlePubMedGoogle Scholar
- de Medina P, Silvente-Poirot S, Poirot M: Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy. 2009, 5: 1066-1067. 10.4161/auto.5.7.9820.View ArticlePubMedGoogle Scholar
- de Medina P, Paillasse MR, Segala G, Khallouki F, Brillouet S, Dalenc F, Courbon F, Record M, Poirot M, Silvente-Poirot S: Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chem Phys Lipids. 2011, 164: 432-437. 10.1016/j.chemphyslip.2011.05.005.View ArticlePubMedGoogle Scholar
- Wen YY, Yang ZQ, Song M, Li BL, Yao XH, Chen XL, Zhao J, Lu YY, Zhu JJ, Wang EH: The expression of SIAH1 is downregulated and associated with Bim and apoptosis in human breast cancer tissues and cells. Mol Carcinog. 2010, 49: 440-449.PubMedGoogle Scholar
- Kutuk O, Letai A: Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ. 2010, 17: 1624-1635. 10.1038/cdd.2010.41.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.